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ABSTRACT
Background: Tuberculosis (TB) remains a major public
health threat worldwide. Numerous cost-effectiveness analy-
ses of TB screening and treatment strategies have been
recently published, but none have utilized quality-adjusted
life-years as recommended because of the lack of utilities for
TB health states.
Objective: To characterize and compare utility scores from
either active TB or latent TB infection (LTBI) participants.
Methods: Consenting patients attending a population-based
screening and treatment clinic were administered the Short
Form 36 (SF-36), the Health Utilities Index 2/3 (HUI2/3), and
a general health visual analog scale (VAS) along with demo-
graphic questions. SF-36 scores were converted to Short
Form 6D (SF-6D) utility scores using an accepted algorithm.
Utility results were compared across scales, and construct
validity was assessed.
Results: A total of 162 TB patients (78 LTBI and 84 active
TB) with available SF-36 and all four utility scores (Health
Utilities Index 2, Health Utilities Index 3, SF-6D and VAS)
were included in the analysis. Those with active TB had
signiﬁcantly lower SF-36 and utility scores than those with
LTBI. Although all appeared to exhibit construct validity, the
HUI2/3 and the VAS appeared to have signiﬁcant ceiling
effects, whereas the SF-6D had signiﬁcant ﬂoor effects.
Conclusions: Health state utility values for active TB and
LTBI have been determined using different instruments. The
three measures did not generate identical utility scores. The
HUI2/3 was limited by ceiling effects, whereas the SF-6D
appeared to display ﬂoor effects.
Keywords: health-related quality of life, health state utility,
HUI-III, SF-36, utility assessment.
Introduction
Although effective chemotherapy is available, world-
wide tuberculosis (TB) remains a major public health
problem, with approximately one-third of the world’s
population infected [1]. In North America, because
mortality due to TB is rare, the avoidance of morbidity
and maintenance of patients’ quality of life has become
the goal of TB management [2,3]. Health-related
quality of life (HRQL) has been introduced into
medical practices and evaluated in many diseases
including TB. There is increasing evidence to show that
TB has substantial and encompassing impacts on
patients’ quality of life [4–9]. Furthermore, clinical
measures often correlate poorly with daily well-being
and function, the areas in which patients are most
interested and familiar.
Two basic approaches to assessing HRQL are avail-
able: generic and disease-speciﬁc instruments [10].
Generic instruments capture the common and impor-
tant aspects of health, while speciﬁc instruments
are designed to focus on unique problems associated
with a disease. One category of generic instruments
is “preference-based” or “utility measure,” and
examples of such are the EuroQol 5D (EQ-5D), the
Health Utilities Index 2 (HUI2) and the Health Utilities
Index 3 (HUI3), and the Short Form 6D (SF-6D).
These instruments summarize HRQL into a single
index number, anchored at 0 (death) and 1 (perfect
health), and are based on societal health preferences.
Scores can then be incorporated into cost-utility analy-
ses (a special type of cost-effectiveness analysis [CEA])
through the calculation of quality-adjusted life-years
(QALYs) that combine the utility score for a health
state (quality of life) with the duration of time spent in
the particular health state (quantity of life).
Recently, there have been many CEAs of the treat-
ment of, and/or screening for, TB infection in popula-
tions such as intravenous drug users [11,12], the
elderly [13], tuberculin reactors stratiﬁed by age
[14,15], immigrants [16–19], and new blood-based
diagnostic strategies [20–22]. So far, none have eva-
luated TB health outcomes in the holistic way
recommended by the inﬂuential US Panel on
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Cost-Effectiveness in Health and Medicine [23],
namely, QALYs constructed from utilities elicited from
TB patients. The main reason for the lack of QALYs as
outcome measures in TB economic evaluations is the
dearth of TB-related utility data in the literature.
Considering the void in the literature regarding
health state utility values for active TB and latent TB
infection (LTBI), the primary purpose of this article
was to characterize and compare utility scores between
the HUI2, HUI3, and SF-6D in a sample of partici-
pants with either active TB or LTBI.
Methods
Study Setting and Subjects
Participants were recruited from the TBClinic at the BC
Center for Disease Control. To be eligible for this study,
the participant had to have a diagnosis of either active
TB or LTBI within 2 months of study entry. Subjects
were excluded if 1) they were less than 18 years old; 2)
they were not taking medication for active TB or LTBI;
or 3) they were judged to be incapable of answering the
questionnaires. This study received ethical approval
from the University of British Columbia Behavioral
Research Ethics Board, and informed signed consent
was obtained from each participant.
During the ﬁrst clinic visit, relevant participants’
information was collected, including 1) sociodemo-
graphics, e.g., age, sex, education, and comorbid
conditions; 2) TB symptoms, medication use, adverse
events, and self-reported TB symptom severity and
control; 3) responses to the HRQL questionnaires
(Short Form 36 [SF-36], HUI2/HUI3, and a visual
analog scale [VAS]). All questionnaires were self-
administered, and the participants were permitted to
take them home for completion. Investigators followed
up by phone call to ensure that questionnaires were
returned within a week.
Assessment of HRQL
SF-36 and SF-6D. The SF-36 Health Survey is one of
the most widely used generic, health proﬁle instruments
[24]. Eight domain scores (physical functioning, role
limitations due to physical health, bodily pain, general
health perceptions, vitality, social functioning, role limi-
tations due to emotional problems, and mental health)
and two summary scores, the physical component
summary (PCS) and the mental component summary
(MCS), are calculated to describe health status. Never-
theless, no single, preference-based index score can be
derived directly from this widely used HRQL instru-
ment. To obtain a preference-based utility score from it,
Brazier et al. restructured the SF-36 into a health state
classiﬁcation systemwith six attributes called the SF-6D
(which includes physical functioning, role limitations,
social functioning, pain, mental health, and vitality).
Each attribute has four to six levels, and therefore the
SF-6D describes 18,000 health states. Scoring is based
on responses froma random sample drawn from theUK
general population.
Health Utilities Index (HUI). HUI is a family of mul-
tiattribute health status classiﬁcation systems that is
currently composed of the HUI2 and HUI3 [25]. HUI2
and HUI3 utility scores are derived from the same
questionnaire, but they contain different health dimen-
sions with various levels in each, and they employ
different samples and scoring models to obtain prefer-
ence scores. HUI2 has seven health attributes (sensa-
tion, mobility, emotion, cognition, self-care, pain, and
fertility), each with three to ﬁve levels [26], while HUI3
consists of eight attributes with ﬁve to six levels within
each. In total, HUI2 deﬁnes 18,000 health states, and
HUI3 deﬁnes 972,000 health states [27]. Preference
scores for both HUI3 and HUI2 health states were
based on Canadian samples using the standard gamble
(SG) and a VAS approach.
In this study, both the HUI and SF-36 question-
naires used “the past 4 weeks” as the response time
frame to minimize potential differences in recall.
VAS. In this study, a horizontal line, 10 cm in length,
anchored at “0” (death) at the left end and “1”
(perfect health) at the right end was used. Each respon-
dent was asked to mark on the line the point that they
felt represented their current health state.
Statistical Analysis
Scores for the SF-6D, HUI3, and HUI2 were calculated
for each patient from the two questionnaires, SF-36
and HUI. All patients who had completed the SF-6D,
HUI3, HUI2, and VAS scores were included in the
analysis. Descriptive summary statistics were used to
describe demographic characteristics. Chi-square tests,
Student’s t test, or analysis of variance (ANOVA), as
appropriate, were used to examine the demographic
differences between active and latent patients. In each
group, patients who were included and those who
were excluded were compared as well.
The SF-36 domain scores and utility scores were
summarized by groups numerically and graphically.
Because the utility scores were usually not normally
distributed, median value and interquartile range were
also presented. Differences between latent and active
patients on SF-36 scores and utility values were tested
using simple linear regression, adjusting for the
available demographic variables. Active TB patients
were then categorized by self-graded TB severity and
control, and each instrument’s ability to discriminate
between severity subgroups was tested.
Two-way ANOVA and paired two-sample t tests
were performed to examine the differences among the
four utility instruments within individuals. The ceiling
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and ﬂoor effects for the three indirect utility instru-
ments (HUI2, HUI3, and SF-6D) were examined from
two aspects: the frequency of possible minimum and
maximum scores for each instrument, and the propor-
tion of respondents who reported the best and
worst level within each single health attribute for each
instrument.
Spearman’s rho was calculated to assess the corre-
lation between various measures. The correlation coef-
ﬁcients were explained as follows. -0.30 to 0.30, weak
correlation; -0.49 to -0.30 and 0.30 to 0.49, moderate
correlation; and <-0.50 and >0.50, strong correlation
[28]. Agreement among the utility scores was assessed
using the intraclass correlation coefﬁcient (ICC) gener-
ated from a two-way mixed-effect ANOVA model
where the patient effect was random and the instru-
ment effect was ﬁxed. The single-measure ICCs were
used and interpreted according to the following guide-
lines: ICC < 0.40, poor agreement; 0.40 to 0.75, mod-
erate to good agreement; >0.75, excellent agreement
[29]. All P-values were two sided, and P < 0.05 was
considered to be statistically signiﬁcant.
Results
Description of Study Sample
In a consecutive fashion, over a 12-month period, we
approached 147 LTBI and 133 active TB patients to
participate in the study. Of these, 119 LTBI and 114
active TB patients were deemed eligible and consented
to participate in the study. Of these, 27 (20 LTBI and 7
active) withdrew from the study before completing
the questionnaires. Subsequent to enrollment, three
patients reported as having active TB were excluded as
they did not ﬁt the entry criteria of having active TB
(under medical surveillance for previously active TB,
not currently active, no documentation of prior medi-
cations, no growth on smear and cultures). Thus, 104
active TB and 99 LTBI participants were enrolled in
the study. Of these, 25 (12.3%) participants failed to
fully complete the SF-36; 15 (7.4%) did not fully com-
plete the HUI, and 13 (6.4%) had no VAS results. In
total, 162 (79.8%) TB patients (78 LTBI and 84 active
TB) with available SF-36 and all four utility scores
(HUI2, HUI3, SF-6D, and VAS) were included in the
analysis. In each group, there were no signiﬁcant dif-
ferences on the studied demographic characteristics
between patients included and those excluded.
The demographic features of both the active TB and
LTBI participants are described in Table 1. Active TB
participants were signiﬁcantly older than LTBI partici-
pants (49.0 vs. 36.3 years, P < 0.01). Subjects with
active TB were more likely to have comorbid condi-
tions (45% vs. 24%, P = 0.02) and to report alcohol
use compared with those with LTBI (86% vs. 69%,
P = 0.01). Overall, of the 162 TB patients in this study,
43% were males; 87% were born outside Canada, and
56% were originally Asians or Paciﬁc Islanders.
SF-36 Scores
In comparison with those with LTBI, subjects with
active TB had a much lower average scores on all eight
domains of the SF-36 (Table 2, all P < 0.05), after
adjusting for the demographic differences between the
two groups. Overall, older participants tended to score
lower than those who were younger, and no sex dif-
ference was observed on SF-36 domain scores in this
sample.
Global Utility Scores
Table 3 summarizes the four sets of global utility scores
for LTBI and active TB participants, respectively. For
each utility instrument assessment, signiﬁcantly lower
average scores were observed in active TB participants
compared with those with LTBI, after account-
ing for the impact of the demographic differences
Table 1 Demographic description of participants
Latent (N = 78) Active (N = 84) P-value
Age (mean in year, SD) 36.3 (11.1) 49.0 (19.0) <0.01
Sex (% male) 40 45 0.48
Foreign-born (%) 85 89 0.38
Race (%) 0.50
Asian or Paciﬁc Islander 51 60
East Indian (South Asian) 17 14
Caucasian 13 15
African American 5.1 3.6
Aboriginal 3.8 1.2
Others 10.1 6.2
Marital status (%) 0.55
Married 47 56
Single 33 27
Others 20 17
Smoking (% yes) 26 23 0.60
Alcohol use (% yes) 69 86 0.01
Drug use (% yes) 10 4.8 0.27
Comorbidity (% yes) 24 45 0.02
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(all P < 0.01). In active TB participants, the four
preference-based instruments (the HUI2, HUI3, SF-6D,
and VAS) yielded signiﬁcantly different global score
within individuals, with HUI2 having the highest
average score overall, followed by HUI3, SF-6D, and
VAS.
Figures 1–4 show the distributions of the global
scores among active TB participants. SF-6D scores
were distributed normally, but with limited available
range, and the observed lowest score was 0.32. In
contrast, HUI2 and HUI3 scores covered a wider
range: -0.26 to 1.00 for HUI3 and 0.13 to 1.00 for
HUI2. Nevertheless, HUI2 and HUI3 scores were
highly skewed toward 1 (perfect health), demonstrat-
ing a ceiling effect. For the HUI2 and HUI3, respec-
tively, 25% and 21% of active participants reported
scores of 1 (perfect health). In contrast, 2.4% of the
participants scored 1 for SF-6D. VAS scores were not
as skewed as HUI2 and HUI3, and spanned the entire
scale range, from 0.08 to 1.00.
Table 4 describes the proportion of respondents at
the best and worst level within each single health
dimension for HUI2, HUI3, and SF-6D. For HUI2 and
HUI3, less than 4% of active TB participants reported
the worst level in all health dimensions, but large pro-
portions of participants were at the best level. There
are three common health dimensions in the HUI2 and
HUI3, which are emotion, cognition, and pain. In the
pain dimension, about 50% of the respondents chose
the best possible level, while in the cognition and
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Figure 1 Distribution of Short Form 6D (SF-6D) scores in active
participants.
Table 2 Short Form 36 scores
Latent (N = 78) Active (N = 84)
Mean (95% CI) Median IQR Mean (95% CI) Median IQR
Physical functioning 54.3 (52.7–55.9) 57.0 0.0 41.2 (38.1–44.4) 40.2 25.3
Role physical 51.9 (49.9–53.8) 56.9 9.2 38.1 (34.7–41.5) 37.3 30.0
Bodily pain 55.7 (53.4–58.0) 62.1 11.0 50.1 (47.3–53.0) 51.1 20.7
General health 52.5 (50.7–54.4) 52.9 9.5 44.5 (42.3–46.7) 44.1 14.3
EN (vitality) 52.7 (50.7–54.8) 52.1 12.5 44.0 (41.0–46.9) 42.7 18.7
Social functioning 52.7 (50.6–54.7) 56.8 5.5 39.5 (36.3–42.7) 40.5 23.2
Role emotional 50.7 (48.6–52.9) 55.9 2.9 35.0 (30.9–39.1) 32.6 35.0
Mental health 50.9 (48.7–53.0) 52.8 14.1 44.4 (41.8–47.0) 43.0 16.9
Physical component summary 54.7 (53.2–56.1) 56.8 6.3 44.8 (42.1–47.5) 45.9 18.9
Mental component summary 50.3 (48.5–52.0) 52.8 8.9 40.1 (37.1–43.1) 41.4 22.0
CI, conﬁdence interval; IQR, interquartile range; MCS, mental component summary; PCS, physical component summary.
Table 3 Global utility scores
Mean (95% CI) Median Min Max IQR
Latent
(N = 78)
SF-6D 0.82 (0.80–0.85) 0.85 0.40 1.00 0.12
HUI3 0.90 (0.86–0.94) 0.97 0.08 1.00 0.10
HUI2 0.93 (0.90–0.95) 0.95 0.49 1.00 0.08
VAS 0.87 (0.84–0.90) 0.90 0.39 1.00 0.20
Active
(N = 84)
SF-6D 0.68 (0.65–0.72) 0.64 0.32 1.00 0.24
HUI3 0.76 (0.70–0.82) 0.90 -0.26 1.00 0.31
HUI2 0.85 (0.80–0.89) 0.93 0.13 1.00 0.19
VAS 0.66 (0.61–0.71) 0.70 0.08 1.00 0.32
CI, conﬁdence interval; HUI2, Health Utilities Index 2; HUI3, Health Utilities Index 3;
IQR, interquartile range; SF-6D, Short Form 6D;VAS, visual analog scale.
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Figure 2 Distribution of Health Utilities Index 3 (HUI3) scores in active
participants.
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emotion dimensions, the respondents chose the best
level of the HUI3 domain much less than the best level
of the HUI2 domain. For SF-6D dimension scores,
except for vitality, all had at least 22% at the best level.
For example, 42% and 33% were at the best level in
the pain and role limitation dimensions, respectively.
On the other hand, 63%, 29%, and 14% were at the
worst level in role limitation, vitality, and social func-
tioning, respectively. Even though the role limitation
dimension has four levels in total, 96% of participants
reported either the best or the worst level, leaving a
gap at the intermediate levels.
In Table 5, SF-36 summary scores and each of the
utility scores were summarized by the level of self-
reported disease severity. Each instrument demon-
strated a clear monotonically decreasing trend in
scores with increasing severity level. Among the four
sets of utility scores, only HUI3 scores were not statis-
tically different between adjacent severity subgroups.
Table 6 presents Spearman’s coefﬁcients for corre-
lation between SF-36 summary scores and the four
global preference-based scores. Strong correlation was
observed between the four utility instrument scores
(0.52–0.86, P < 0.0001). In terms of the relationship
with SF-36, SF-6D scores were strongly correlated
with both PCS and MCS (0.79, 0.80), while HUI3 and
HUI2 were strongly correlated with PCS (0.59, 0.66),
but only moderately correlated with MCS (0.37, 0.48).
The overall ICC among the four utility instrument
scores was 0.65, indicating good agreement. ICCs (and
95% conﬁdence intervals) between each paired utility
score are presented in Table 7. There was excellent
agreement between HUI2 and HUI3 (0.84). The agree-
ment between all other paired utility scores was good
(0.53–0.67).
Discussion
This study has generated much needed evidence
regarding preference-based utility scores for subjects
with active TB and LTBI that can be integrated into
cost-utility analyses of TB diagnostic and treatment
interventions. In addition, this study provides some
comparative information regarding the different
methods of estimating health utilities and aids in the
choice of measure to be included in primary studies.
Finally, the results show that there are signiﬁcant
problems with all of the instruments in terms of ﬂoor
and ceiling effects especially when each domain is
considered.
Other authors have estimated preferences for health
states in TB either through expert opinion [15,30] or by
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Figure 3 Distribution of Health Utilities Index 2 (HUI2) scores in active
participants.
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Figure 4 Distribution of visual analog scale (VAS) scores in active
participants.
Table 4 Frequency of reporting the best and worst levels in
active participants (N = 84)
Utility
instruments
Best level,
no. (%)
Worst level,
no. (%)
HUI2
Sensation 51 (60.7) 3 (3.6)
Mobility 60 (71.4) 0
Emotion 59 (70.2) 0
Cognition 61 (72.6) 1 (1.2)
Self-care 77 (91.7) 2 (2.4)
Pain 42 (50.0) 1 (1.2)
HUI3
Vision 53 (63.1) 2 (2.4)
Hearing 82 (97.6) 1 (1.2)
Speech 77 (91.7) 0
Ambulation 60 (71.4) 0
Dexterity 70 (94.0) 0
Emotion 35 (41.7) 0
Cognition 19 (22.6) 1 (1.2)
Pain 42 (50.0) 2 (2.4)
SF-6D
Physical function 22 (26.2) 5 (6.0)
Role limitation 28 (33.3) 53 (63.1)
Social function 25 (29.8) 12 (14.3)
Pain 35 (41.7) 6 (7.1)
Mental health 19 (22.6) 4 (4.8)
Vitality 6 (7.1) 24 (28.6)
HUI2, Health Utilities Index 2; HUI3, Health Utilities Index 3; SF-6D, Short Form 6D.
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surveying the general public [31]. Nevertheless, only
one other study has attempted to measure health pref-
erences from patients with LTBI and active, or recently
cured, TB [7]. These authors relied on a small, hetero-
geneous sample of LTBI (N = 25), active TB (N = 17)
and previous active TB (N = 8) participants to derive
health state utility values, thus limiting the generaliz-
ability of their ﬁndings. Furthermore, the authors uti-
lized the SG, a VAS, and the EQ-5D to elicit health state
preferences and the SF-36 as a general health measure.
In general, their ﬁndings were that those with concur-
rent active TB rated hypothetical health states (mild,
moderate, and severe) lower than those with LTBI and
previously active TB. Also SG scores correlated poorly
with the EQ-5D and the SF-36, andmoderatelywith the
VAS. The authors concluded that the SG was likely a
more comprehensive measure of HRQL because it was
not limited to a small number of domains and levels like
questionnaire-based instruments are and provides a
more holistic assessment of HRQL. Nevertheless, there
are recent publications that put the validity and the
reliability of the SG into question when used in speciﬁc
patient populations [32,33]. As such, it is not clear that
the SG is appropriate for the elicitation of utility values
in all cases.
From the same data set, the authors published
another article whose purpose was to evaluate the
feasibility and reliability of the EQ-5D and the SF-36
[6]. They found that the proportion of acceptable SF-36
questionnaires was 78% versus 90% for the EQ-5D. In
addition, they found a high degree of internal consis-
tency for the SF-36 and a high test–retest reliability.
Similar to our study, the authors were concerned about
the use of health status questionnaires in amulticultural
sample which are not adapted and tested in the
respondent’s native language. Nevertheless, because
the authors found a low frequency of inconsistent
responses and high internal consistency, they concluded
that it was valid to use these questionnaires. Similarly,
authors of other articles [34,35] found similar high
feasibility and strong psychometric properties for the
SF-36 in nonnative English language speakers.
It was difﬁcult to compare the VAS scores from
our sample to that of Dion et al.’s because of the lack
of stratiﬁcation in the presentation of their results
into subjects with LTBI and active TB [6,7]. Never-
theless, we found the VAS to be much more highly
correlated with the PCS (r = 0.65) and the MCS
(r = 0.58) than Dion et al. whose correlations were
0.54 and 0.32, respectively.
Within our results, the utility global scores were
signiﬁcantly different with the HUI2 generating the
highest and the SF-6D providing the lowest mean
scores. The distribution of SF-6D scores was much
more symmetrical than that of HUI3 or HUI2, but
within a very limited scale range, from 0.32 to 1.00. In
contrast, HUI3 scores spanned approximately twice
the range of SF-6D scores, and HUI2 distributed from
Table 5 Short Form 36 and utility scores by self-reported TB severity and control, mean and SD
PCS MCS SF-6D HUI3 HUI2 VAS
Severity of TB symptoms
Very mild 54.5 (6.6) 52.4 (7.6) 0.84 (0.11) 0.93 (0.10) 0.94 (0.07) 0.84 (0.14)
Mild 50.0 (5.2) 44.6 (10.1) 0.68 (0.05) 0.84 (0.19) 0.93 (0.08) 0.75 (0.09)
Moderate 44.6 (9.5) 34.5 (12.6) 0.64 (0.10) 0.73 (0.28) 0.83 (0.19) 0.65 (0.13)
Severe 35.6 (12.0) 33.8 (12.4) 0.59 (0.15) 0.65 (0.36) 0.76 (0.25) 0.54 (0.22)
Very severe 32.5 (11.8) 28.9 (10.8) 0.54 (0.08) 0.53 (0.37) 0.71 (0.28) 0.35 (0.21)
Control of TB symptoms
Very well controlled 55.8 (6.0) 51.8 (7.8) 0.85 (0.09) 0.90 (0.16) 0.94 (0.07) 0.84 (0.15)
Well controlled 49.3 (6.3) 47.7 (9.6) 0.73 (0.13) 0.92 (0.08) 0.95 (0.07) 0.74 (0.18)
Adequately controlled 40.0 (12.7) 32.3 (11.7) 0.60 (0.11) 0.68 (0.30) 0.78 (0.21) 0.60 (0.18)
Not well controlled 33.9 (8.7) 30.2 (11.9) 0.56 (0.11) 0.52 (0.38) 0.74 (0.27) 0.42 (0.22)
Not controlled at all — — — — — —
HUI2, Health Utilities Index 2; HUI3, Health Utilities Index 3; MCS,mental component summary; PCS, physical component summary; SF-6D, Short Form 6D;TB, tuberculosis;VAS,
visual analog scale.
Table 6 Correlation (Spearman’s rho) between Short Form 36
and utility instruments
PCS MCS SF-6D HUI3 HUI2 VAS
PCS 1.00
MCS 0.45 1.00
SF-6D 0.79 0.80 1.00
HUI3 0.66 0.48 0.71 1.00
HUI2 0.59 0.37 0.59 0.90 1.00
VAS 0.67 0.59 0.65 0.58 0.52 1.00
All P < 0.0001.
HUI2,Health Utilities Index 2;HUI3,Health Utilities Index 3;MCS,mental component
summary; PCS, physical component summary; SF-6D, Short Form 6D; VAS, visual
analog scale.
Table 7 Intraclass correlations between the four utility
instruments
SF-6D HUI3 HUI2 VAS
SF-6D 1.00
HUI3 0.63 (0.53–0.72) 1.00
HUI2 0.67 (0.58–0.75) 0.84 (0.79–0.88) 1.00
VAS 0.66 (0.56–0.74) 0.56 (0.45–0.66) 0.53 (0.41–0.63) 1.00
HUI2, Health Utilities Index 2; HUI3, Health Utilities Index 3; SF-6D, Short Form 6D;
VAS, visual analog scale.
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0.13 to 1.00. Although having a wider scale range than
SF-6D, HUI3 and HUI2 scores were highly skewed
toward 1.00, with 25% and 21% participants report-
ing a HUI2 and HUI3 score of 1.0, respectively, indi-
cating a possible ceiling effect in active TB participants.
There was no evidence to demonstrate a ceiling or
ﬂoor effect for SF-6D global utility scores, because
only 2.4% of participants reported perfect health and
none reported the worst health state. Nevertheless, a
dimension-speciﬁc analysis SF-6D yielded possible
ﬂoor effects. The most notable result was in the role
limitation dimension. In the pain dimension, all three
instruments demonstrated a signiﬁcant ceiling effect,
with 42% at the best level for SF-6D, and 50% for
HUI2 and HUI3. Compared to SF-6D, all HUI2 and
HUI3 single dimensions demonstrated ceiling effects
with very limited ﬂoor effects.
Discrepancies between scores of the indirect utility
instruments have been observed and discussed in other
patient populations [36,37]. These discrepancies may
arise because of the internal differences of the utility
instruments, such as the health dimensions covered,
the methods of obtaining preferences (such as the SG
or the time trade-off techniques), and the application
of the instruments. Each instrument focuses on differ-
ent health dimensions with various levels within each
dimension and can have different recall periods.
Nevertheless, despite these differences, some simi-
larities have been observed as well. The correlation
between these instruments was from moderate to
strong, suggesting that they are likely measuring
similar concepts of health. The four utility instruments
were able to discriminate TB participants with differ-
ent severity levels. In general, the average utility scores
showed a decrease with the increasing disease severity.
In conclusion, health state utility values for active
TB and LTBI have been determined using different
instruments. The three measures, the HUI2, HUI3, and
SF-6D, did not generate identical utility scores in active
TB or LTBI participants. The biggest concern with the
HUI2 and HUI3 was the ceiling effect, and SF-6D was
limited by its narrow range of utility values available
and the potential ﬂoor effect. As such, the HUI2 and
HUI3 may be more able to evaluate HRQL in more
severe participants because the SF-6D does not appear
to adequately capture health states at the lower end of
the scale.
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